Our program to address FAP and APC mutant colon cancers includes TURBO-ZM™ based molecules ZKN-013 and ZKN-074.
- 8-week study in APCMin mice planned to evaluate potential of RMAs to treat FAP
FAP is caused by a mutation in the adenomatous polyposis coli (APC) gene coding for APC protein, which acts as a tumor suppressor and keeps cells from growing too fast or in an uncontrolled way.
It is characterized by polyps developing as early as the teens.1-3
80% OF CRC PATIENTS 80% OF CRC PATIENTS
have an APC mutation.
Erythromycin treatment
shown to reduce both
the amount and size
of polyps
Response to ZKN-013
shown in tumor grafts
ex-vivo from patients
with FAP derived CRC
TURBO-ZM™ is a trademark of Eloxx Pharmaceuticals, Inc.
©2022 Eloxx Pharmaceuticals, Inc.
Produced in the USA.
February 2022
